Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CARLSMED, INC.CARL · Entity 5551 | Director | June 03, 2026 | June 22, 2026 |
| GenMark Diagnostics, Inc.GNMK · Entity 140086 | Director | April 22, 2021 | April 22, 2021 |
| Outset Medical, Inc.OM · Entity 7026 | Director | June 04, 2026 | June 05, 2026 |
| Sientra, Inc.SIEN · Entity 108294 | Director | June 09, 2022 | June 14, 2022 |
| iRhythm Holdings, Inc.IRTC · Entity 1499 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CARLSMED, INC.
Report date June 03, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,031 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 13,698 · Balance 31,031 F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
GenMark Diagnostics, Inc.
Report date April 22, 2021 · Filed April 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 1
1 source rowRow 1 · 2021-04-22 · Other · Disposed 131,678 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F2: Includes 28,128 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2022-01-03 | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-22 · Disposition to issuer · Disposed 13,426 · Balance 0 F3: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Includes 28,128 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU.
F3: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof.
Outset Medical, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,785 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,667 · Balance 34,785 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders
Sientra, Inc.
Report date June 09, 2022 · Filed June 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,978 |
Reported balance
After 2022-06-09 transaction · row 1
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 103,306 · Balance 220,978 F1: The Restricted Stock Units shall vest on the earlier to occur of: (i) the day prior to the 2023 Annual Shareholders Meeting or (ii) on the one (1) year anniversary of the Annual Shareholders Meeting on which the Restricted Stock Award was granted, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units shall vest on the earlier to occur of: (i) the day prior to the 2023 Annual Shareholders Meeting or (ii) on the one (1) year anniversary of the Annual Shareholders Meeting on which the Restricted Stock Award was granted, subject to continued service.
iRhythm Holdings, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,608 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 1,573 · Balance 3,608 F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 43,396 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Wright Medical Group N.V.
Report date November 11, 2020 · Filed November 13, 2020
Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 1
1 source rowRow 1 · 2020-11-11 · Other · Disposed 16,306 · Balance 0 F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 26,063 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-11 · Disposition to issuer · Disposed 11,691 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-11 · Disposition to issuer · Disposed 9,907 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-11 · Disposition to issuer · Disposed 10,275 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-11 · Disposition to issuer · Disposed 11,765 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-11 · Disposition to issuer · Disposed 11,018 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.66 · Expires 2024-08-12 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-11 · Disposition to issuer · Disposed 6,034 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.45 · Expires 2023-08-09 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-11 · Disposition to issuer · Disposed 7,538 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.04 · Expires 2022-08-10 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-11 · Disposition to issuer · Disposed 6,448 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.20 · Expires 2021-05-12 | Direct | 0 |
Reported balance
After 2020-11-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-11 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 26,063 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Other · Disposed 11,985 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, out of the total of 11,985 shares held by the Reporting Person, (i) 10,952 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,033 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2022-06-14 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-28 · Other · Disposed 1,391 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.21 · Expires 2021-07-28 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-28 · Other · Disposed 40,871 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.34 · Expires 2023-06-18 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-04-28 · Other · Disposed 10,645 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2024-05-29 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-28 · Other · Disposed 30,000 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, out of the total of 11,985 shares held by the Reporting Person, (i) 10,952 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,033 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.
F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 22:14 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 10,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-26-000035 · edgardoc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,785 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| June 03, 2026 Filed Jun 22, 2026 10:13 UTC | CARLSMED, INC. CARL · Entity 5551 | GrantCommon Stock | 13,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-276633 · ownership.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,031 F1 · shares: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:02 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | GrantCommon Stock | 1,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001203567-26-000003 · wk-form4_1780084972.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,608 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of IRTC Common Stock. The vesting occurs on the earlier of (i) one year after grant or the (ii) the date of the company's next annual meeting. Read SEC document |
| July 22, 2025 Filed Jul 25, 2025 00:29 UTC | CARLSMED, INC. CARL · Entity 5551 | GrantCommon Stock | 17,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-098533 · ownership.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,333 F1 · shares: Constitute an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in equal annual installments over three years. F2 · shares: Includes 17,333 unvested restricted stock units convertible into approximately 17,333 shares of the Issuer's common stock. F2 · balance_after: Includes 17,333 unvested restricted stock units convertible into approximately 17,333 shares of the Issuer's common stock. Read SEC document |
| July 07, 2025 Filed Jul 8, 2025 20:22 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | GrantCommon Stock | 2,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001388658-25-000184 · wk-form4_1752006159.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,035 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 33.33% of the RSUs vest on July 7, 2026 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:29 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 8,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-25-000057 · edgardoc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,118 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| May 14, 2025 Filed May 14, 2025 21:06 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 15,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-25-000040 · edgardoc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,135 F1 · shares: Represents Restricted Stock Units ("RSUs") granted to the reporting person on May 14, 2025. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest quarterly over three years, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | Disposition to issuerCommon Stock | 43,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050464 · ownership.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:55 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 19,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000264 · form4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,396 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 23, 2024 or (ii) the next Annual Meeting following May 23, 2024, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 19,169 RSUs. Read SEC document |
| May 25, 2023 Filed May 30, 2023 17:24 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 6,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000078 · form4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,227 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2023 or (ii) the next Annual Meeting following May 25, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 6,754 RSUs. Read SEC document |
| June 09, 2022 Filed Jun 14, 2022 00:05 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock | 103,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036505 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,978 F1 · shares: The Restricted Stock Units shall vest on the earlier to occur of: (i) the day prior to the 2023 Annual Shareholders Meeting or (ii) on the one (1) year anniversary of the Annual Shareholders Meeting on which the Restricted Stock Award was granted, subject to continued service. Read SEC document |
| May 26, 2022 Filed May 27, 2022 21:00 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011888 · doc1.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,473 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 26, 2022 or (ii) the next Annual Meeting following May 26, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 4,155 restricted stock units. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 17:58 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 1,400 | $83.80 | $117,320.00 |
DisclosureSEC source: 0001567619-21-022198 · doc1.xml · nonDerivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,318 F1 · balance_after: Includes 3,183 restricted stock units. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 17:58 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 1,000 | $83.75 | $83,750.00 |
DisclosureSEC source: 0001567619-21-022198 · doc1.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,918 F1 · balance_after: Includes 3,183 restricted stock units. Read SEC document |
| June 10, 2021 Filed Jun 16, 2021 00:17 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock | 16,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040774 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,672 F1 · shares: The Restricted Stock Units shall vest on the earlier to occur of: (i) the day prior to the 2022 Annual Shareholders Meeting or (ii) on the one (1) year anniversary of the Annual Shareholders Meeting on which the Restricted Stock Award was granted, subject to continued service. F2 · price: Each restricted stock unit represents a contingent right to receive one share of Sientra, Inc. Class A Common Stock. Read SEC document |
| May 25, 2021 Filed May 26, 2021 21:00 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011222 · doc1.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,918 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2021 or (ii) the next Annual Meeting following May 25, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 3,183 RSUs. Read SEC document |
| April 22, 2021 Filed Apr 22, 2021 13:54 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,426 | Not disclosed Strike: $4.38 | Not disclosed |
DisclosureSEC source: 0001487371-21-000178 · wf-form4_161911404825662.xml · derivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,426 shares Expires 2022-01-03 F3 · price: The Merger Agreement provides that each Option granted pursuant to a Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be accelerated and vest in full and (ii) to the extent not exercised prior to the Merger Effective Time, be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such canceled Option will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of (a) the number of Shares subject to such Option multiplied by (b) the excess, if any, of the Offer Price over the exercise price per Share under such Option; provided that, if the exercise price per Share of any such Option is equal to or greater than the Offer Price, then such Option will be canceled without any cash payment being made in respect thereof. Read SEC document |
| April 22, 2021 Filed Apr 22, 2021 13:54 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | OtherCommon Stock | 131,678 | $24.05 | $3,166,855.90 |
DisclosureSEC source: 0001487371-21-000178 · wf-form4_161911404825662.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated March 12, 2021, by and among Roche Holdings, Inc., a Delaware corporation ("Parent"), Geronimo Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"), and GenMark Diagnostics, Inc., a Delaware corporation (the "Company") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Parent caused Purchaser to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $24.05 per share (the "Offer Price"). On April 22, 2021 (the "Merger Effective Time"), the Company irrevocably accepted for payment all shares that were validly tendered and not withdrawn. F2 · shares: Includes 28,128 RSUs. The Merger Agreement provides that each RSU awarded pursuant to any Company Plan, whether vested or unvested, that is outstanding immediately prior to the Merger Effective Time, will automatically (i) be fully accelerated and vest in full and the restrictions thereon shall lapse and (ii) be canceled and terminated as of the Merger Effective Time, and, in exchange therefor, each former holder of any such RSU will be entitled to receive an amount in cash (without interest and subject to any deduction for required withholding taxes) equal to the product of the Offer Price multiplied by the number of Shares subject to such RSU. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 18:09 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 10,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-21-000050 · wf-form4_161377615935557.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,678 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2020 Equity Incentive Plan, which vest in full on June 1, 2022. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 7,800 | Not disclosed Strike: $25.20 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 10 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,800 shares Expires 2021-05-12 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 6,448 | Not disclosed Strike: $18.04 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 9 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,448 shares Expires 2022-08-10 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 7,538 | Not disclosed Strike: $19.45 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 8 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,538 shares Expires 2023-08-09 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 6,034 | Not disclosed Strike: $21.66 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 7 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,034 shares Expires 2024-08-12 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 11,018 | Not disclosed Strike: $20.62 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 6 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,018 shares Expires 2025-10-13 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 11,765 | Not disclosed Strike: $21.24 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 5 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,765 shares Expires 2026-07-19 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 10,275 | Not disclosed Strike: $27.86 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 4 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,275 shares Expires 2027-07-25 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 9,907 | Not disclosed Strike: $24.49 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 3 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,907 shares Expires 2028-07-24 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | Disposition to issuerStock Option (right to buy) · Derivative | 11,691 | Not disclosed Strike: $27.84 | Not disclosed |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · derivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,691 shares Expires 2029-07-26 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 15:51 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | OtherOrdinary Shares, par value EUR 0.03 per share | 16,306 | $30.75 | $501,409.50 |
DisclosureSEC source: 0001790300-20-000004 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 26,063 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:25 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock (RSUs) | 27,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035378 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,802 F1 · shares: The Restricted Stock Units (RSUs) will vest on the earlier to occur of: (i) the day prior to the Annual Meeting for the fiscal year following the date of grant or (ii) the one (1) year anniversary of the Annual Meeting on which the Annual Grant was granted, subject to continued service as a director of the Issuer. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 17:58 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 17,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-20-000199 · wf-form4_159113510817637.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,548 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2020 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 14:32 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011148 · doc1.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,751 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2020 or (ii) the next Annual Meeting following May 21, 2020, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 5,408 restricted stock units. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 11:22 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | PurchaseCommon Stock | 10,800 | $4.53 | $48,924.00 |
DisclosureSEC source: 0001487371-20-000096 · wf-form4_158376732566820.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,550 F1 · price: The price reported is the weighted average price per share. Shares were purchased in multiple transactions at prices ranging from $4.52 to $4.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 20:52 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 3,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-20-000060 · wf-form4_158285474210927.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,750 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan in connection with his appointment as Chair of the Board of Directors, which vest in full on May 31, 2020. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 16,150 | $6.51 | $105,136.50 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · nonDerivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,962 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person in June 2019. F3 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $6.50 to $6.54. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,050 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · derivative · entry 8 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,050 shares Expires 2020-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The Reporting Person was issued 1,180 shares of the Company's common stock pursuant to the net exercise of designated stock options. As a result, the Company withheld 16,870 shares of common stock underlying the exercised stock option for the payment of the exercise price using the closing stock price on August 15, 2019 of $6.42 per share, pursuant to the terms of the Company's 2010 Equity Incentive Plan. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · derivative · entry 7 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2020-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was issued 1,635 shares of the Company's common stock pursuant to the net exercise of the designated stock options. As a result, the Company withheld 23,365 shares of common stock underlying the exercised stock options for the payment of the exercise price using the closing stock price on August 15, 2019 of $6.42 per share, pursuant to the terms of the Company's 2010 Equity Incentive Plan. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Tax withholdingCommon Stock | 16,870 | $6.42 | $108,305.40 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · nonDerivative · entry 6 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,777 F5 · kind: The Reporting Person was issued 1,180 shares of the Company's common stock pursuant to the net exercise of designated stock options. As a result, the Company withheld 16,870 shares of common stock underlying the exercised stock option for the payment of the exercise price using the closing stock price on August 15, 2019 of $6.42 per share, pursuant to the terms of the Company's 2010 Equity Incentive Plan. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Tax withholdingCommon Stock | 23,365 | $6.42 | $150,003.30 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · nonDerivative · entry 5 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,647 F4 · kind: The Reporting Person was issued 1,635 shares of the Company's common stock pursuant to the net exercise of the designated stock options. As a result, the Company withheld 23,365 shares of common stock underlying the exercised stock options for the payment of the exercise price using the closing stock price on August 15, 2019 of $6.42 per share, pursuant to the terms of the Company's 2010 Equity Incentive Plan. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionCommon Stock | 18,050 | $6.00 | $108,300.00 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · nonDerivative · entry 4 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | Exercise / conversionCommon Stock | 25,000 | $6.00 | $150,000.00 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · nonDerivative · entry 3 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 17:15 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | SaleCommon Stock | 2,200 | $6.51 | $14,322.00 |
DisclosureSEC source: 0001487371-19-000188 · wf-form4_156624930628938.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,112 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person in June 2019. F2 · price: The price reported is the weighted average price per share. Shares were sold in multiple transactions at prices ranging from $6.50 to $6.53. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 16:55 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantStock Option (right to buy) · Derivative | 11,691 | $0.00 Strike: $27.84 | $0.00 |
DisclosureSEC source: 0001235802-19-000083 · primary_doc.xml · derivative · entry 2 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,691 Underlying: Ordinary Shares · 11,691 shares Expires 2029-07-26 Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 16:55 UTC | Wright Medical Group N.V. WMGI · Entity 145358 | GrantOrdinary Shares, par value EUR 0.03 per share | 3,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-19-000083 · primary_doc.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,306 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. F2 · balance_after: Includes 3,916 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 23:40 UTC | Sientra, Inc. SIEN · Entity 108294 | GrantCommon Stock (RSUs) | 19,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037837 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,085 F1 · shares: The Restricted Stock Units (RSUs) will vest on the earlier to occur of: (i) the day prior to the Annual Meeting for the fiscal year following the date of grant or (ii) the one (1) year anniversary of the Annual Meeting on which the Annual Grant was granted, subject to continued service as a director of the Issuer. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 20:50 UTC | Sientra, Inc. SIEN · Entity 108294 | PurchaseCommon Stock | 8,696 | $5.75 | $50,002.00 |
DisclosureSEC source: 0001209191-19-036111 · doc4.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,765 Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:30 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 1,675 | $60.00 | $100,500.00 |
DisclosureSEC source: 0001567619-19-013060 · doc1.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,375 F1 · balance_after: Includes 6,049 restricted stock units. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 16:21 UTC | GenMark Diagnostics, Inc. GNMK · Entity 140086 | GrantCommon Stock | 19,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001487371-19-000163 · wf-form4_155967969865439.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,312 F1 · shares: The amount reported reflects restricted stock units granted to the Reporting Person pursuant to the Issuer's 2010 Equity Incentive Plan, which vest in full on the first anniversary of the grant date. Read SEC document |
| May 20, 2019 Filed May 22, 2019 18:00 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 6,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-011870 · doc1.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. RSUs shall vest in three (3) equal annual installments on each anniversary of March 19, 2019, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 6,049 RSUs. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:36 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 651 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007426 · doc1.xml · nonDerivative · entry 1 OBOYLE KEVIN C · CIK 0001203567 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651 F1 · balance_after: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the next Annual Meeting of the Stockholders following March 19, 2019, subject to the Reporting Person's continued service to the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.